Page 195 - 2018_11-Haematologica-web

Glycosylation modulates FVIII immunogenicity
to FVIII-specific IgM and IgG, that may, in turn, facilitate the formation of immune complexes in the circulation. Collectively, our studies provide an additional biological complement to evidence presented in recent epidemio- logical investigations showing that 2nd generation BHK- rFVIII is more immunogenic than 3rd generation CHO- rFVIII.
Funding
This work was supported by an Operating and Foundation Grant from the Canadian Institutes of Health Research (MOP-10912, FDN-154285), GlycoNet, and from the Canadian Hemophilia Society. JDL is supported in part by an Ontario Graduate Scholarship and the Franklin Bracken Fellowship. and DL is the recipient of a Canada Research Chair in Molecular Hemostasis.
References
1. Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor develop- ment in severe hemophilia A. N Engl J Med. 2013;368(3):231-239.
2. Collins PW, Palmer BP, Chalmers E a, et al. Factor VIII brand and the incidence of fac- tor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood. 2014;1 24 (23): 3389- 3397.
3. Calvez T, Virginie H, Milien V, Rothschild C. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124(23):3398-3409.
4. Calvez T, Chambost H, D’Oiron R, et al. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant fac- tor VIII brands in boys with severe hemo- philia A. Haematologica. 2018; 103(1):179- 189.
5. Lai J, Hough C, Tarrant J, Lillicrap D. Biological considerations of plasma-derived and recombinant factor VIII immunogenic- ity. Blood. 2017;129(24):3147-3154.
6. van Haren SD, Herczenik E, ten Brinke A, Mertens K, Voorberg J, Meijer AB. HLA- DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII. Mol Cell Proteomics. 2011; 10(6):M110.002246.
7. Steinitz KN, van Helden PM, Binder B, et al. CD4+ T-cell epitopes associated with anti- body responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA- DRB1*1501 mice. Blood. 2012; 119(17):4073-4082.
8. Healey JF, Parker ET, Lollar P. Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultra- centrifugation. J Thromb Haemost. 2018; 16(2):303-315.
9. Pisal DS, Kosloski MP, Middaugh CR, Bankert RB, Balu-iyer S V. Native-like aggregates of factor VIII are immunogenic in von Willebrand Factor deficient and hemophilia A mice.. J Pharm Sci. 2012; 101(6):2055-2065.
10. Vehar G, Keyt B, Eaton D, Rodriguez H. Structure of human factor VIII. Nature. 1984;312(5992):337-342.
11. Moussalli M, Pipe SW, Hauri HP, Nichols WC, Ginsburg D, Kaufman RJ. Mannose- dependent endoplasmic reticulum (ER)- Golgi intermediate compartment-53-medi- ated ER to Golgi trafficking of coagulation factors V and VIII. J Biol Chem. 1999; 274(46):32539-32542.
12. Pipe SW, Morris J a, Shah J, Kaufman RJ. Differential Interaction of Coagulation Factor VIII and Factor V with Protein Chaperones Calnexin and Calreticulin. J
Biol Chem. 1998;273(14):8537-8544.
13. Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJM, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J
Thromb Haemost. 2005;3(6):1257-1265. 14. Pegon JN, Kurdi M, Casari C, et al. Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5.
Haematologica. 2012;97(12):1855-1863.
15. Dasgupta S, Navarrete A-M, Bayry J, et al. A role for exposed mannosylations in pres- entation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad
Sci USA. 2007;104(21):8965-8970.
16. Herczenik E, van Haren SD, Wroblewska A, et al. Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain. J Allergy Clin Immunol. 2012;
129(2):501-509.e5.
17. Delignat S, Dasgupta S, Andre S, et al.
Comparison of the immunogenicity of dif- ferent therapeutic preparations of human factor VIII in the murine model of hemo- philia A. Haematologica. 2007;92(10):1423- 1426.
18. Delignat S, Repessé Y, Gilardin L, et al. Predictive immunogenicity of Refacto AF. Haemophilia. 2014;20(4):486-492.
19. Kosloski MP, Miclea RD, Balu-Iyer S V. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J. 2009;11(3):424-431.
Proc Natl Acad Sci USA. 1992; 89(9):3795-
3799.
27. Whelan SFJ, Hofbauer CJ, Horling FM, et al.
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood. 2013; 121(6):1039-1048.
28. Hironaka T, Furukawa K, Esmon PC, et al. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem. 1992;267(12):8012-8020.
29. Kannicht C, Ramstrom M, Kohla G, et al. Characterisation of the post-translational modifications of a novel, human cell line- derived recombinant human factor VIII. Thromb Res. 2013;131(1):78-88.
30. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A. Implications of the pres- ence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol. 2010;28(8):863-867.
31. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358(11):1109-1117.
32. Pahl S, Pavlova A, Driesen J, Müller J, Pötzsch B, Oldenburg J. In vitro characteri- zation of recombinant factor VIII concen- trates reveals significant differences in pro- tein content, activity and thrombin activa- tion profile. Haemophilia. 2013; 19(3):392-
20. Bril WS, van Helden PMW, Hausl C, et al. 398.
Tolerance to factor VIII in a transgenic mouse expressing human factor VIII cDNA carrying an Arg 593 to Cys substitution. Thromb Haemost. 2006;95(2):341-347.
21. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted dis- ruption of the mouse factor VIII gene pro- duces a model of haemophilia A. Nat Genet. 1995;10(1):119-121.
22. Hausl C, Maier E, Schwarz HP, et al. Long- term persistence of anti-factor VIII anti- body-secreting cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost. 2002;87(5):840-845.
23. Lai JD, Moorehead PC, Sponagle K, et al. Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A. Blood. 2016;1 27(26):3439- 3449.
24. van Den Brink EN, Turenhout E a, Davies J, et al. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood. 2000; 95(2):558-563.
25. Raut S, Bevan S, Hubbard AR, Sands D, Barrowcliffe TW. A collaborative study to establish the 7th International Standard for Factor VIII Concentrate. J Thromb Haemost. 2005;3(1):119-126.
26. Algiman M, Dietrich G, Nydegger UE, Boieldieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (anti- hemophilic factor) in healthy individuals.
33. Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046-4055.
34. Qadura M, Waters B, Burnett E, et al. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood. 2009;114(4):871-880.
35. Navarrete A, Dasgupta S, Delignat S, et al. Splenic marginal zone antigen-presenting cells are critical for the primary allo- immune response to therapeutic factor VIII in hemophilia A. J Thromb Haemost. 2009; 7(11):1816-1823.
36. Henri S, Vremec D, Kamath A, et al. The dendritic cell populations of mouse lymph nodes. J Immunol. 2001;167(2):741-748.
37. Noe DA. A Mathematical Model of Coagulation Factor VIII Kinetics. Pathophysiol Haemost Thromb 1996; 26(6):289-303.
38. Medzihradszky KF, Besman MJ, Burlingame a L. Structural characterization of site-specific N-glycosylation of recombi- nant human factor VIII by reversed-phase high-performance liquid chromatography- electrospray ionization mass spectrometry. Anal Chem. 1997;69(19):3986-3994.
39. Lenting PJ, Pegon JN, Christophe OD, Denis C V. Factor VIII and von Willebrand factor--too sweet for their own good.
haematologica | 2018; 103(11)
1935